Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER
Butt J, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Koeber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2024, 45: ehae666.1097. DOI: 10.1093/eurheartj/ehae666.1097.Peer-Reviewed Original ResearchEffects of dapagliflozinT2D durationHeart failureEjection fractionPrimary outcomeDAPA-HFCardiovascular deathNew York Heart Association functional classPro-B-type natriuretic peptide levelsN-terminal pro-B-type natriuretic peptide levelsComposite of worsening HFLeft ventricular ejection fractionPatient-level pooled analysisRisk of worsening HFAssociated with worse outcomesDuration of type 2 diabetesSafety of dapagliflozinPatient-level meta-analysisBenefits of dapagliflozinNatriuretic peptide levelsVentricular ejection fractionReduced ejection fractionHistory of T2DDuration of HFDuration of T2D